ReviewAmerican journal of clinical dermatology2026
Mastering the Use of Systemic JAK Inhibitors for Atopic Dermatitis: A Dermatologist's Practical Guide.
Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is one of the most frequent conditions treated by dermatologists. The therapeutic options for moderate-to-severe AD are rapidly expanding with the introduction of biologics and Janus kinase inhibitors (JAKis). There are currently three oral JAKis approved for the treatment of AD, namely abrocitinib, baricitinib and upadacitinib. Although JAKis are rapidly effective for treating AD and its symptoms, they require careful patient selection and monitoring due to a side-effect profile which includes an increased risk of major adverse cardiovascular events (MACE) and malignancies, especially in patients with pre-existing risk factors. The aim of this article is to provide practical recommendations on how to prescribe, monitor and manage potential adverse reactions of systemic JAKis for AD, and to assist dermatologists in navigating various scenarios that can be encountered in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.